We observed strong selection for KRAS-12D over time, which was further enhanced by the EGF receptor inhibitor gefitinib, reflecting the clinical importance of KRAS-12D mutation as a resistance mechanism for anti-EGF receptor therapy in colon cancer (Fig. 4f). Here, KRAS is linked to colonic neoplasm.